{"transactions":[{"id":804304,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Dr. Koppel's continued service through each such vesting date."}],"balance_after":38300,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804303,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":4145768,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4145768},"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804302,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":16875000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16875000},"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804301,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":1562500,"price":16,"value":25000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":22583268,"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804300,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":4145768,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":21020768,"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804299,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":16875000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":16875000,"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":1440926,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T16:49:16.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80189,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":80189},"source":{"system":"sec-edgar","filing":"0000950170-24-090903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090903/ownership.xml","form_type":"4"}},{"id":1440925,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T16:49:16.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65679781,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of common stock held directly by BC Perception Holdings, LP (\"BC Perception\"). Adam Koppel is a Partner of Bain Capital Life Sciences Investors, LLC. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090903/ownership.xml","form_type":"4"}},{"id":1440924,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T16:49:16.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10461,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are represented by restricted stock units (\"RSUs\"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares are represented by restricted stock units (\"RSUs\"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090903/ownership.xml","form_type":"4"}},{"id":1440923,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T16:49:16.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3282,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":10461,"source":{"system":"sec-edgar","filing":"0000950170-24-090903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090903/ownership.xml","form_type":"4"}},{"id":1467015,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:00:47.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005356","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000156218024005356/primarydocument.xml","form_type":"4"}},{"id":1486985,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T17:12:05.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10461,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the\nIssuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the\nIssuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company."}],"balance_after":13743,"source":{"system":"sec-edgar","filing":"0000950170-24-070855","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024070855/ownership.xml","form_type":"4"}},{"id":1680020,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-12T21:56:49.000Z","date":"2024-01-11","kind":"grant","planned":false,"acquired":true,"shares":904160,"price":5.53,"value":5000004.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 8, 2024, BCLS II Equity Opportunities, LP (\"BCLS II Equity\") entered into a securities purchase agreement with the Issuer pursuant to which the Issuer agreed to issue and sell 904,160 shares of Common Stock to BCLS II Equity at a price of $5.53 per share (the \"January 2024 Private Placement\"). The January 2024 Private Placement closed on January 11, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of Common Stock held by BCLS SB Investco, LP (\"BCLS SB\"), Bain Capital Life Sciences Fund II, L.P. (\"BCLS Fund II\"), BCLS II Investco, LP (\"BCLS II Investco\"), BCLS II Equity and BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS SB, BCLS Fund II, BCLS II Investco and BCLS II Equity, the \"Bain Capital Life Sciences Entities\"). Bain Capital Life Sciences Investors, LLC (\"BCLSI\") (i) is the ultimate general partner of each of BCLS SB, BCLS Fund II, BCLS II Investco and BCLS II Equity and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Koppel is a Partner of BCLSI. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":4034582,"source":{"system":"sec-edgar","filing":"0000950170-24-004276","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017024004276/ownership.xml","form_type":"4"}},{"id":1758183,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-18T16:30:12.000Z","date":"2023-10-16","kind":"purchase","planned":false,"acquired":true,"shares":5480052,"price":22.81,"value":124999986.12,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP (\"BC Perception\"). Adam Koppel is a Partner of Bain Capital Life Sciences Investors, LLC. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":65679781,"source":{"system":"sec-edgar","filing":"0000899243-23-019971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323019971/doc4.xml","form_type":"4"}},{"id":1846182,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:12:08.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005476","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000156218023005476/primarydocument.xml","form_type":"4"}},{"id":1860750,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T17:07:05.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":13780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":13780,"derivative":{"exercise_price":32.6,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":13780},"source":{"system":"sec-edgar","filing":"0000899243-23-015220","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323015220/doc4.xml","form_type":"4"}},{"id":1860749,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T17:07:05.000Z","date":"2023-06-07","kind":"other","planned":false,"acquired":false,"shares":432627,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On June 7, 2023, BC Perception Holdings, LP (\"BC Perception\") distributed an aggregate of 432,627 shares of the Issuer's common stock (the \"Distributed Shares\") to certain of its limited partners in a pro-rata in-kind distribution to such limited partners in connection with a redemption of their partnership interests. Dr. Koppel did not have a pecuniary interest in any of the Distributed Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Adam Koppel is a Partner of Bain Capital Life Sciences Investors, LLC, which is the ultimate general partner of Bain Capital Life Sciences Fund, L.P. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":60199729,"source":{"system":"sec-edgar","filing":"0000899243-23-015220","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323015220/doc4.xml","form_type":"4"}},{"id":1860748,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T17:07:05.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":3282,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":3282,"source":{"system":"sec-edgar","filing":"0000899243-23-015220","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323015220/doc4.xml","form_type":"4"}},{"id":1862417,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-08T21:01:01.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":9650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":9650,"derivative":{"exercise_price":6.37,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":9650},"source":{"system":"sec-edgar","filing":"0000950170-23-027058","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017023027058/ownership.xml","form_type":"4"}},{"id":2085166,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-12-15T23:19:51.000Z","date":"2022-12-13","kind":"grant","acquired":true,"shares":9650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":9650,"derivative":{"exercise_price":6.47,"expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":9650},"source":{"system":"sec-edgar","filing":"0000899243-22-038700","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924322038700/doc4.xml","form_type":"4"}},{"id":2096187,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-12-05T22:16:27.000Z","date":"2022-12-02","kind":"grant","acquired":true,"shares":2666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 2, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":2666,"derivative":{"exercise_price":6.77,"expiration_date":"2032-12-01","underlying":"Common Stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0000899243-22-037648","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924322037648/doc4.xml","form_type":"4"}},{"id":2223775,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-06-23T00:59:17.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":13.81,"exercise_date":"2023-06-21","expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-22-005314","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000156218022005314/primarydocument.xml","form_type":"4"}},{"id":2230082,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T17:10:52.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":23459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":23459,"derivative":{"exercise_price":24.35,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":23459},"source":{"system":"sec-edgar","filing":"0000899243-22-022864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322022864/doc4.xml","form_type":"4"}},{"id":2251438,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T17:06:34.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in ratable monthly installments over one year from the date of grant, subject to the director's continued service with the Issuer."}],"balance_after":40000,"derivative":{"exercise_price":0.5,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-22-020206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924322020206/doc4.xml","form_type":"4"}},{"id":2456865,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-12-29T16:43:55.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":30.47,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-21-050036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321050036/doc4.xml","form_type":"4"}},{"id":2456864,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-12-29T16:43:55.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":21.61,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-21-050036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321050036/doc4.xml","form_type":"4"}},{"id":2456863,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-12-29T16:43:55.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":15.44,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-050036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321050036/doc4.xml","form_type":"4"}},{"id":2456862,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-12-29T16:43:55.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":13.08,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-050036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321050036/doc4.xml","form_type":"4"}},{"id":2456861,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-12-29T16:43:55.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":3.47,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-050036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321050036/doc4.xml","form_type":"4"}},{"id":2456860,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-12-29T16:43:55.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":3.42,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-050036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321050036/doc4.xml","form_type":"4"}},{"id":2456859,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-12-29T16:43:55.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":3333,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0000899243-21-050036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321050036/doc4.xml","form_type":"4"}},{"id":2456858,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-29T16:43:55.000Z","date":"2021-12-28","kind":"other","acquired":false,"shares":3080237,"price":38.25,"value":117819065.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of December 28, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of December 28, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of December 28, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of common stock held directly by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Koppel is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Koppel may be deemed to share voting and dispositive power with respect to the Shares held by the Bain Capital Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-050036","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321050036/doc4.xml","form_type":"4"}},{"id":2456857,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-29T16:43:55.000Z","date":"2021-12-28","kind":"other","acquired":false,"shares":3333,"price":38.25,"value":127487.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of December 28, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of December 28, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of December 28, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-050036","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321050036/doc4.xml","form_type":"4"}},{"id":2605004,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-13T00:38:04.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":1000000,"price":70.25,"value":70250000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock held directly by BC SW, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":4831307,"source":{"system":"sec-edgar","filing":"0000899243-21-032893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924321032893/doc4.xml","form_type":"4"}},{"id":2628212,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C1 Preferred Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"exercise","acquired":false,"shares":6672819,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 6,053,214 shares of the Issuer's Series C1 Preferred Stock held by BCLS and 619,605 shares of the Issuer's Series C1 Preferred Stock held by BCIPLS, which were automatically converted into 1,210,642 and 123,920 shares of the Issuer's Class A Common stock, respectively, immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1334562},"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2628211,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B1 Preferred Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"exercise","acquired":false,"shares":35000001,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 31,750,072 shares of the Issuer's Series B1 Preferred Stock held by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 3,249,929 shares of the Issuer's Series B1 Preferred Stock held by BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\"), which were automatically converted into 6,350,013 and 649,985 shares of the Issuer's Class A Common Stock, respectively, immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":6999998},"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2628210,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"purchase","acquired":true,"shares":100000,"price":20,"value":2000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents 90,714 and 9,286 shares of the Issuer's Class A Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":8434560,"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2628209,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"exercise","acquired":true,"shares":1334562,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 6,053,214 shares of the Issuer's Series C1 Preferred Stock held by BCLS and 619,605 shares of the Issuer's Series C1 Preferred Stock held by BCIPLS, which were automatically converted into 1,210,642 and 123,920 shares of the Issuer's Class A Common stock, respectively, immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":8334560,"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2628208,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"exercise","acquired":true,"shares":6999998,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 31,750,072 shares of the Issuer's Series B1 Preferred Stock held by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 3,249,929 shares of the Issuer's Series B1 Preferred Stock held by BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\"), which were automatically converted into 6,350,013 and 649,985 shares of the Issuer's Class A Common Stock, respectively, immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":6999998,"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2633822,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-14T20:53:36.000Z","date":"2021-07-13","kind":"grant","acquired":true,"shares":12530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in full on the first anniversary of the date of grant, subject to the director's continued service on our Board of Directors."}],"balance_after":12530,"derivative":{"exercise_price":9.4,"exercise_date":"2022-07-13","expiration_date":"2031-07-12","underlying":"Common Stock","underlying_shares":12530},"source":{"system":"sec-edgar","filing":"0001562180-21-004935","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000156218021004935/primarydocument.xml","form_type":"4"}},{"id":2661170,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right To Buy)","published_at":"2021-06-21T21:15:11.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":30000,"derivative":{"exercise_price":3.94,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-21-025027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924321025027/doc4.xml","form_type":"4"}},{"id":2670345,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T20:25:08.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":42950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":42950,"derivative":{"exercise_price":13.93,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":42950},"source":{"system":"sec-edgar","filing":"0000899243-21-023729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924321023729/doc4.xml","form_type":"4"}},{"id":2678869,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-06-07T18:50:48.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over 12 months from the date of grant , provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer  as a director through each applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":30.47,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-21-022369","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321022369/doc4.xml","form_type":"4"}},{"id":2678868,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-07T18:50:48.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in full on the earlier of (i) 12 months from the date of grant and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in full on the earlier of (i) 12 months from the date of grant and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in full on the earlier of (i) 12 months from the date of grant and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs do not expire."}],"balance_after":3333,"derivative":{"underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0000899243-21-022369","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321022369/doc4.xml","form_type":"4"}},{"id":2678867,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-07T18:50:48.000Z","date":"2021-06-03","kind":"exercise","acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in full on the earlier of (i) 12 months from the date of grant and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in full on the earlier of (i) 12 months from the date of grant and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in full on the earlier of (i) 12 months from the date of grant and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs do not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0000899243-21-022369","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321022369/doc4.xml","form_type":"4"}},{"id":2678866,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-07T18:50:48.000Z","date":"2021-06-03","kind":"exercise","acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3333,"source":{"system":"sec-edgar","filing":"0000899243-21-022369","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924321022369/doc4.xml","form_type":"4"}},{"id":2689023,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option(Right Buy)","published_at":"2021-06-01T16:30:13.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in ratable monthly installments over one year from the date of grant, subject to the director's continued service with the Issuer."}],"balance_after":40000,"derivative":{"exercise_price":2.59,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-021320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924321021320/doc4.xml","form_type":"4"}},{"id":2772000,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-25T20:30:14.000Z","date":"2021-03-23","kind":"grant","acquired":true,"shares":869565,"price":5.75,"value":4999998.75,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 23, 2021, BCLS purchased 869,565 shares of common stock of the Issuer at a price per share of $5.75, pursuant to an underwritten public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"On March 23, 2021, BCLS purchased 869,565 shares of common stock of the Issuer at a price per share of $5.75, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock held directly by BCLS SB Investco, LP (\"BCLS\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of BCLS. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":7929918,"source":{"system":"sec-edgar","filing":"0000899243-21-013476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924321013476/doc4.xml","form_type":"4"}},{"id":2794103,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:30:16.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":1450000,"price":71.5,"value":103675000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock held directly by BC SW, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Schwartz is a director of the Issuer."}],"balance_after":5831307,"source":{"system":"sec-edgar","filing":"0000899243-21-011153","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924321011153/doc4.xml","form_type":"4"}},{"id":2920680,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right Buy)","published_at":"2021-01-05T16:44:09.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":5508,"price":2.224,"value":12249.792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's nonemployee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested at time of grant."}],"balance_after":5508,"derivative":{"exercise_price":3.46,"expiration_date":"2030-12-30","underlying":"Common Stock","underlying_shares":5508},"source":{"system":"sec-edgar","filing":"0000899243-21-000400","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924321000400/doc4.xml","form_type":"4"}},{"id":2946068,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-14T17:35:47.000Z","date":"2020-12-10","kind":"sale","acquired":false,"shares":1000000,"price":23.4,"value":23400000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock held directly by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process on behalf of BCIP LS. Dr. Koppel is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by the Bain Capital Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3080237,"source":{"system":"sec-edgar","filing":"0000899243-20-033765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924320033765/doc4.xml","form_type":"4"}},{"id":2948740,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-11T21:30:07.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":3189189,"price":3.7,"value":11799999.3,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 10, 2020, BCLS purchased 3,189,189 shares of common stock directly from the Issuer at a price per share of $3.70."},{"field":"shares","element":"transactionShares","label":"F3","text":"On December 10, 2020, BCLS purchased 3,189,189 shares of common stock directly from the Issuer at a price per share of $3.70."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock held directly by BCLS SB Investco, LP (\"BCLS\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of BCLS. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":7060353,"source":{"system":"sec-edgar","filing":"0000899243-20-033569","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924320033569/doc4.xml","form_type":"4"}},{"id":2984110,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-12T17:54:39.000Z","date":"2020-11-09","kind":"purchase","acquired":true,"shares":332293,"price":10.3,"value":3422617.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 9, 2020, BC Perception Holdings, LP (\"BC Perception\") purchased 332,293 shares of the Issuer's Common Stock at a price of $10.30 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Adam Koppel is a Managing Director of Bain Capital Life Sciences Investors, LLC, which is the ultimate general partner of Bain Capital Life Sciences Fund, LP. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":60632356,"source":{"system":"sec-edgar","filing":"0000899243-20-030860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924320030860/doc4.xml","form_type":"4"}},{"id":2998185,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-29T20:00:15.000Z","date":"2020-10-27","kind":"purchase","acquired":true,"shares":10000000,"price":10,"value":100000000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 27, 2020, BC Perception purchased 10,000,000 shares of the Issuer's Common Stock from the Issuer at a price of $10.00 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Adam Koppel is a Managing Director of Bain Capital Life Sciences Investors, LLC, which is the ultimate general partner of Bain Capital Life Sciences Fund, LP. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":60300063,"source":{"system":"sec-edgar","filing":"0000899243-20-029742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924320029742/doc4.xml","form_type":"4"}},{"id":2998184,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-29T20:00:15.000Z","date":"2020-10-27","kind":"other","acquired":true,"shares":49961943,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 27, 2020, Cerevel Therapeutics Holdings Inc. (f/k/a ARYA Sciences Acquisition Corp II, the \"Issuer\") consummated a business combination (the \"Business Combination\") pursuant to which Cassidy Merger Sub 1, Inc., a wholly-owned subsidiary of the Issuer merged with and into Cerevel Therapeutics, Inc. (\"Cerevel\"). At the effective time of the Business Combination, each share of Cerevel outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Cerevel vested equity value of $780,000,000. As a result, BC Perception Holdings, LP (\"BC Perception\") received 49,961,943 shares of the Issuer's Common Stock in consideration for the equity securities of Cerevel held by BC Perception prior to the Business Combination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 27, 2020, Cerevel Therapeutics Holdings Inc. (f/k/a ARYA Sciences Acquisition Corp II, the \"Issuer\") consummated a business combination (the \"Business Combination\") pursuant to which Cassidy Merger Sub 1, Inc., a wholly-owned subsidiary of the Issuer merged with and into Cerevel Therapeutics, Inc. (\"Cerevel\"). At the effective time of the Business Combination, each share of Cerevel outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Cerevel vested equity value of $780,000,000. As a result, BC Perception Holdings, LP (\"BC Perception\") received 49,961,943 shares of the Issuer's Common Stock in consideration for the equity securities of Cerevel held by BC Perception prior to the Business Combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Adam Koppel is a Managing Director of Bain Capital Life Sciences Investors, LLC, which is the ultimate general partner of Bain Capital Life Sciences Fund, LP. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":50300063,"source":{"system":"sec-edgar","filing":"0000899243-20-029742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924320029742/doc4.xml","form_type":"4"}},{"id":2999318,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-27T21:07:36.000Z","date":"2020-10-26","kind":"purchase","acquired":true,"shares":3333333,"price":3,"value":9999999.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 26, 2020, Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and BCIP Life Sciences Fund, LP (\"BCIPLS and, together with BCLS, the \"Bain Capital Life Sciences Entities\") purchased an aggregate of 3,333,333 shares of Common Stock in an underwritten public offering at a price per share of $3.00. BCLS purchased 3,023,816 of such shares and BCIPLS purchased 309,517 of such shares. Following such purchases, BCLS holds 8,066,113 shares of Common Stock and BCIPLS holds 825,645 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Adam Koppel is a director of the Issuer."}],"balance_after":8891758,"source":{"system":"sec-edgar","filing":"0000899243-20-029321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320029321/doc4.xml","form_type":"4"}},{"id":3000207,"issuer":{"id":145747,"kind":"organization","name":"BCLS Acquisition Corp.","symbol":"BLSA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A ordinary shares","published_at":"2020-10-26T16:30:15.000Z","date":"2020-10-26","kind":"grant","acquired":true,"shares":487500,"price":10,"value":4875000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported Class A ordinary shares were purchased from the Issuer in a private placement by BCLS Acquisition Holdings, LP (the \"Sponsor\") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-249284)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the Sponsor. The Sponsor is controlled by its general partner, BCLS Acquisition Holdings (GP), LLC (the \"General Partner\"), which is governed by a board of managers consisting of three managers. Each manager has one vote, and the approval of a majority of the managers is required to approve an action on behalf of the Sponsor. Adam Koppel serves on the board of managers of the General Partner. As a result, Dr. Koppel may be deemed to share beneficial ownership of the shares held by the Sponsor. Dr. Koppel disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":487500,"source":{"system":"sec-edgar","filing":"0000899243-20-029241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1823200/000089924320029241/doc4.xml","form_type":"4"}},{"id":3016360,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-02T16:15:09.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":5663,"price":2.163,"value":12249.069,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested at time of grant."}],"balance_after":5663,"derivative":{"exercise_price":3.38,"expiration_date":"2030-09-29","underlying":"Common Stock","underlying_shares":5663},"source":{"system":"sec-edgar","filing":"0000899243-20-026850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924320026850/doc4.xml","form_type":"4"}},{"id":3074856,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":2812543,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 2,551,384 shares of Series D Stock held of record by BCLS and 261,159 shares of Series D Stock held of record by BCIPLS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":319243},"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3074855,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":22222221,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 20,158,775 shares of Series C Stock held of record by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 2,063,446 shares of Series C Stock held of record by BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2522385},"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3074854,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":400000,"price":17,"value":6800000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents 362,858 and 37,142 shares of the Issuer's Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":3241628,"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3074853,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":319243,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 2,551,384 shares of Series D Stock held of record by BCLS and 261,159 shares of Series D Stock held of record by BCIPLS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2841628,"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3074852,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":2522385,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 20,158,775 shares of Series C Stock held of record by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 2,063,446 shares of Series C Stock held of record by BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2522385,"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3092031,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right Buy)","published_at":"2020-07-02T16:06:14.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":4370,"price":2.677,"value":11698.49,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option award was issued to the Reporting P erson, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's nonemployee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested at time of grant."}],"balance_after":4370,"derivative":{"exercise_price":4.17,"expiration_date":"2030-06-29","underlying":"Common Stock","underlying_shares":4370},"source":{"system":"sec-edgar","filing":"0000899243-20-018263","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924320018263/doc4.xml","form_type":"4"}},{"id":3105627,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right To Buy)","published_at":"2020-06-18T21:00:27.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 16, 2020 to members of the Clinical Committee of the Board of Directors and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"This option was granted on June 16, 2020 to members of the Clinical Committee of the Board of Directors and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":10000,"derivative":{"exercise_price":3.03,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-017092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924320017092/doc4.xml","form_type":"4"}},{"id":3105626,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right To Buy)","published_at":"2020-06-18T21:00:27.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2020 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":30000,"derivative":{"exercise_price":3.03,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924320017092/doc4.xml","form_type":"4"}},{"id":3108511,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-16T20:09:08.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option vests in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting."}],"balance_after":15000,"derivative":{"exercise_price":21.61,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-20-016737","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924320016737/doc4.xml","form_type":"4"}},{"id":3108510,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-16T20:09:08.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest 12 months from June 15, 2020 (\"Grant Date\"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest 12 months from June 15, 2020 (\"Grant Date\"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest 12 months from June 15, 2020 (\"Grant Date\"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":3333,"derivative":{"underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0000899243-20-016737","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924320016737/doc4.xml","form_type":"4"}},{"id":3137370,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T16:15:40.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option vests in ratable monthly installments over one year from the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in ratable monthly installments over one year from the date of grant."}],"balance_after":40000,"derivative":{"exercise_price":3.84,"expiration_date":"2030-05-19","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-20-013996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924320013996/doc4.xml","form_type":"4"}},{"id":3186712,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option\n(Right to Buy)","published_at":"2020-04-02T16:58:16.000Z","date":"2020-03-31","kind":"grant","acquired":true,"shares":8296,"price":1.356,"value":11249.376,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested at time of grant."}],"balance_after":8296,"derivative":{"exercise_price":2.16,"expiration_date":"2030-03-30","underlying":"Common Stock","underlying_shares":8296},"source":{"system":"sec-edgar","filing":"0000899243-20-009988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924320009988/doc4.xml","form_type":"4"}},{"id":3286596,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":859573,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 779,758 shares of Series C Stock held of record by BCLS and 79,815 shares of Series C Stock held of record by BCIPLS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":859573},"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3286595,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":2825602,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 2,563,231 shares of Series B Stock held of record by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 262,371 shares of Series B Stock held of record by BCIP Life Sciences Associates, LP. (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2825602},"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3286594,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"purchase","acquired":true,"shares":294117,"price":17,"value":4999989.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents 266,807 and 27,310 shares of Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":3979292,"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3286593,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":859573,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 779,758 shares of Series C Stock held of record by BCLS and 79,815 shares of Series C Stock held of record by BCIPLS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":3685175,"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3286592,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":2825602,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 2,563,231 shares of Series B Stock held of record by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 262,371 shares of Series B Stock held of record by BCIP Life Sciences Associates, LP. (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2825602,"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3309629,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-16T16:20:57.000Z","date":"2020-01-14","kind":"purchase","acquired":true,"shares":3333333,"price":3,"value":9999999.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 14, 2020, the Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, collectively, the \"Bain Life Sciences Entities\") purchased, in the aggregate, 3,333,333 shares of Common Stock of the Issuer at a price of $3.00 per share, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of Common Stock held directly by the Bain Life Sciences Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the ultimate general partner of BCLS and governs the investment strategy and decision making process with respect to investments held by BCIP LS. Dr. Koppel is a manager of BCLSI. By virtue of the relationships described in this footnote, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by the Bain Life Sciences Entities. Dr. Koppel disclaims beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":5558425,"source":{"system":"sec-edgar","filing":"0000899243-20-001322","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924320001322/doc4.xml","form_type":"4"}},{"id":3349395,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-06T17:00:30.000Z","date":"2019-12-04","kind":"sale","acquired":false,"shares":1500000,"price":24.68,"value":37020000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock held directly by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process on behalf of BCIP LS. Dr. Koppel is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by the Bain Capital Life Sciences Entities.  Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":4080237,"source":{"system":"sec-edgar","filing":"0000899243-19-028697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924319028697/doc4.xml","form_type":"4"}},{"id":3363085,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-21T21:26:43.000Z","date":"2019-11-19","kind":"sale","acquired":false,"shares":1750000,"price":22.03,"value":38552500.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 19, 2019 Bain Capital Life Sciences Fund, L.P. (\"BC LS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, together with BC LS, the \"Bain Capital Life Sciences Entities\") sold 1,582,973 and 167,027 shares of common stock, respectively, pursuant to Rule 144 under the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Koppel is a director of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Life Sciences Partners, LP (\"BC LS P\") is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS.  BC LS P disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC LS P and governs the investment strategy and decision-making process with respect to investments held by BCIP LS, whose general partner is Boylston Coinvestors, LLC.  As a result of the relationships described herein, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":5580237,"source":{"system":"sec-edgar","filing":"0000899243-19-027786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924319027786/doc4.xml","form_type":"4"}},{"id":3409667,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":1053204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1053204},"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3409666,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":6078103,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6078103},"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3409665,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":150000,"price":18,"value":2700000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":7281307,"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3409664,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":1053204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":7131307,"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3409663,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":6078103,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":6078103,"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3453328,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T20:37:15.000Z","date":"2019-07-30","kind":"grant","acquired":true,"shares":1881720,"price":4.65,"value":8749998.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 30, 2019, BCLS purchased 1,881,720 shares of common stock directly from the Issuer at a price per share of $4.65."},{"field":"shares","element":"transactionShares","label":"F3","text":"On July 30, 2019, BCLS purchased 1,881,720 shares of common stock directly from the Issuer at a price per share of $4.65."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock held directly by BCLS SB Investco, LP (\"BCLS\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of BCLS. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by BCLS.  Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3871164,"source":{"system":"sec-edgar","filing":"0000899243-19-020588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924319020588/doc4.xml","form_type":"4"}},{"id":3480992,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-06-21T20:02:47.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly over 12 months from June 20, 2019 (\"Grant Date\") in substantially equal monthly installments, provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such date or, if earlier, such annual meeting."}],"balance_after":25000,"derivative":{"exercise_price":15.44,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-19-017865","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924319017865/doc4.xml","form_type":"4"}},{"id":3487814,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director of Stock Option  Right To Buy","published_at":"2019-06-17T20:26:11.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 13, 2019 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":10000,"derivative":{"exercise_price":5.26,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-19-017188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924319017188/doc4.xml","form_type":"4"}},{"id":3506435,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T20:15:40.000Z","date":"2019-05-29","kind":"sale","acquired":false,"shares":1600000,"price":12.5,"value":20000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 29, 2019, Bain Capital Life Sciences Fund, L.P. (\"BC LS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, together with BC LS, the \"Bain Life Sciences Entities\") sold 1,447,289 and 152,711 shares of common stock, respectively, directly to a private investor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Koppel is a director of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Life Sciences Partners, LP (\"BC LS P\") is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. BC LS P disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC LS P and governs the investment strategy and decision-making process with respect to investments held by BCIP LS, whose general partner is Boylston Coinvestors, LLC. As a result of the relationships described herein, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":7330237,"source":{"system":"sec-edgar","filing":"0000899243-19-015281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924319015281/doc4.xml","form_type":"4"}},{"id":3521167,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-17T17:29:11.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in ratable monthly installments over one year from the date of grant."}],"balance_after":40000,"derivative":{"exercise_price":3.73,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-19-014027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924319014027/doc4.xml","form_type":"4"}},{"id":3729159,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-12-17T21:46:45.000Z","date":"2018-12-13","kind":"grant","acquired":true,"shares":8165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":8165,"derivative":{"exercise_price":23.58,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":8165},"source":{"system":"sec-edgar","filing":"0000899243-18-031228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924318031228/doc4.xml","form_type":"4"}},{"id":3860033,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-07-27T20:36:47.000Z","date":"2018-07-25","kind":"grant","acquired":true,"shares":1835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":1835,"derivative":{"exercise_price":37.89,"expiration_date":"2028-07-25","underlying":"Common Stock","underlying_shares":1835},"source":{"system":"sec-edgar","filing":"0000899243-18-020742","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924318020742/doc4.xml","form_type":"4"}},{"id":3860935,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-07-26T20:27:37.000Z","date":"2018-07-24","kind":"exercise","acquired":false,"shares":235146,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the \"Bain Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2338968},"source":{"system":"sec-edgar","filing":"0000899243-18-020659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924318020659/doc4.xml","form_type":"4"}},{"id":3860934,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-26T20:27:37.000Z","date":"2018-07-24","kind":"purchase","acquired":true,"shares":500000,"price":15,"value":7500000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On July 24, 2018, the Bain Life Sciences Entities purchased, in aggregate, 500,000 shares of Common Stock of the Issuer at a price of $15 per share, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the \"Bain Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2838968,"source":{"system":"sec-edgar","filing":"0000899243-18-020659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924318020659/doc4.xml","form_type":"4"}},{"id":3860933,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-26T20:27:37.000Z","date":"2018-07-24","kind":"exercise","acquired":true,"shares":2338968,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the \"Bain Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2338968,"source":{"system":"sec-edgar","filing":"0000899243-18-020659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924318020659/doc4.xml","form_type":"4"}},{"id":3883151,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-26T16:50:25.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":50347397,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the \"Bain Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by the Bain Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1825092},"source":{"system":"sec-edgar","filing":"0000899243-18-018155","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924318018155/doc4.xml","form_type":"4"}},{"id":3883150,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:50:25.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":400000,"price":16,"value":6400000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On June 25, 2018, the Bain Life Sciences Entities purchased, in aggregate, 400,000 shares of Common Stock of the Issuer at a price of $16.00 per share, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the \"Bain Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by the Bain Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":2225092,"source":{"system":"sec-edgar","filing":"0000899243-18-018155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924318018155/doc4.xml","form_type":"4"}},{"id":3883149,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:50:25.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1825092,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the \"Bain Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by the Bain Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1825092,"source":{"system":"sec-edgar","filing":"0000899243-18-018155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000089924318018155/doc4.xml","form_type":"4"}},{"id":3883844,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-25T16:19:41.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly over 12 months from June 21, 2018 (\"Grant Date\") in substantially equal monthly installments, provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such date or, if earlier, such annual meeting."}],"balance_after":25000,"derivative":{"exercise_price":13.08,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-017923","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924318017923/doc4.xml","form_type":"4"}},{"id":3927886,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-17T21:10:10.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.84,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-031035","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429560/000120919118031035/doc4.xml","form_type":"4"}},{"id":4081935,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"LLC Units","published_at":"2018-02-02T00:07:24.000Z","date":"2018-01-25","kind":"exercise","acquired":false,"shares":1991097,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by BCLS SB Investco, LP (\"BCLS\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1689444},"source":{"system":"sec-edgar","filing":"0000899243-18-002535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924318002535/doc4.xml","form_type":"4"}},{"id":4081934,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"LLC Units","published_at":"2018-02-02T00:07:24.000Z","date":"2017-10-26","kind":"grant","acquired":true,"shares":1223240,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the \"Corporate Conversion\"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7.  As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by BCLS SB Investco, LP (\"BCLS\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1991097,"derivative":{"underlying":"Common Stock","underlying_shares":1037919},"source":{"system":"sec-edgar","filing":"0000899243-18-002535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924318002535/doc4.xml","form_type":"4"}}],"next_cursor":"2018-02-02T00:07:24.000000Z,4081934"}